Clinical Trial Update: Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating AMG 562 in relapsed/refractory DLBCL, MCL, or follicular lymphoma was terminated; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Mantle Cell Lymphoma

Drugs mentioned

• AMG 562 (AMG 562)

Snippet

Sponsor: Amgen | Conditions: Diffuse Large B-cell Lymphoma(DLBCL), Mantle Cell Lymphoma (MCL) | Phase 1 | Status: TERMINATED | Results posted: 2024-03-22